SAN DIEGO, Aug. 5, 2020 /PRNewswire/ -- Mesa Biotech, Inc., a privately-held, molecular diagnostic company that has developed an affordable, easy-to-use, point-of-care (POC) testing platform designed specifically for point-of-need settings, today announced it has been awarded up to $15.4 million in funding from the National Institutes of Health (NIH)'s Rapid Acceleration of Diagnostics (RADxSM) initiative to further accelerate the scale-up and deployment of its Accula™ SARS-CoV-2 Test. The Accula SARS-CoV-2 Test is a visually read molecular diagnostic test that provides reliable results within approximately 30 minutes. The test received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) in late March 2020 for use at the point-of-care. The funding will support Mesa Biotech's efforts to further scale-up manufacturing capacity to produce millions of tests per month and expand the company's commercial distribution capabilities to ensure the Accula system is widely available at the point-of-care. "We are extremely pleased to receive this award from the NIH RADx initiative," said Hong Cai, Co-founder and Chief Executive Officer of Mesa Biotech. "This funding will allow us to significantly expand our manufacturing capabilities and increase the availability of our rapid, molecular POC test to help address the COVID-19 pandemic. We believe the Accula system's ease-of-use and speed, combined with its proven accuracy, makes it an ideal solution for a wide range of point-of-care settings." The Accula SARS-CoV-2 Test is currently being used at a wide range of healthcare facilities, including hospitals, urgent care centers, physician offices, skilled nursing facilities, and mobile testing sites. The system is also being deployed in non-traditional settings, such as workplaces, schools, and community centers. About Mesa Biotech, Inc. Mesa Biotech designs, develops, manufactures and commercializes next generation molecular diagnostic tests, bringing the power of the laboratory to the point-of-need. Mesa Biotech's Accula™ platform allows for rapid, molecular diagnostic testing in virtually any setting. The Accula Flu A/Flu B and RSV tests have obtained CE Mark in Europe and the Accula SARS-CoV-2 test has received Emergency Use Authorization from the FDA for use at the point-of-care. Mesa Biotech has also received a CE Mark for the Accula Flu A/Flu B/RSV tests. For more information visit mesabiotech.com. About RADx The NIH RADx initiative is a nationwide program to accelerate the development, commercialization, and implementation of technologies for COVID-19 testing. The program is supported by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) and other NIH components. Media Contact: Joleen Schultz joleen@joleenschultzassociates.com Cell: 760-271-8150